Humoral immune responses to gag and env proteins from human immunodeficiency virus type 1 in hemophiliac patients

Janet S. Kinney, James H. Conway, Margaret W. Hilgartner, Barbara Clayman, Kumudini Mayur, Robert H. Yolken, Raphael P. Viscidi

Research output: Contribution to journalArticle

Abstract

Solid‐phase enzyme immunoassays using recombinant gag and env proteins were developed to study humoral immune responses to HIV infection in a cohort of 105 hemophiliac patients. Thirteen patients with ARC or AIDS and 92 asymptomatic patients were studied. A cross‐sectional study showed a wide range of antibody responses to gag and env proteins; however, the differences between the ARC/AIDS and asymptomatic patients were statistically significant for both antigens (P < .0004). In a longitudinal study, antibody levels in sera from 11 asymptomatic patients with gag antibody log units ≦ 1.5 were compared to levels in sera from 10 ARC/AIDS patients and 8 asymptomatic patients with gag antibody >1.5. These patient groups were followed for comparable periods of time (67.1‐71.7 mo). The asymptomatic patients with low gag antibody and the ARC/AIDS patients showed a similar pattern of antibody response to gag protein overtime. In hemophiliac patients with HIV‐1 infection a low titer of antibody to gag protein is not invariably associated with clinical deterioration and is not a useful serologic marker of impending progression to AIDS.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalAmerican journal of hematology
Volume36
Issue number1
DOIs
StatePublished - Jan 1991

Keywords

  • AIDS
  • anti‐gag antibody
  • hemophilia
  • human immunodeficiency virus

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Humoral immune responses to gag and env proteins from human immunodeficiency virus type 1 in hemophiliac patients'. Together they form a unique fingerprint.

  • Cite this